The term signe de cils was introduced in the late 19th century and is attributed to Achille Souques, one of the most prominent French neurologists of his time.1 This clinical observation reflects the ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...

CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), today announces a new payer coverage agreement with Highmark, effective April 1, ...

How does the brain clean itself during sleep? A new ultrafast MRI method tracks cerebrospinal fluid flow without contrast ...

NeuroTherapia has concluded its Phase IIa clinical trial of NTRX-07, an orally available molecule, for Alzheimer's disease ...

Unprecedented,” “remarkable” and “transformative” were just a few of the descriptives tossed out by Wall Street analysts in response to Revolution Medicines Inc.’s phase III readout, showing RAS ...

Findings suggest that regular physical activity and adequate sleep may lower dementia risk, emphasizing the need for evidence-based lifestyle guidelines.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the 'Company”), a clinical-stage pharmaceutical company developing targeted ...

Functional near‑infrared spectroscopy (fNIRS) enables noninvasive monitoring of brain activity by measuring changes in blood ...

Statistically significant immune response and recurrence rate data is the basis for new claims recently filed that GLSI-100 clinically benefits non-HLA-A*02 patients, which the Company believes ...

An experimental drug designed to silence a gene strongly linked to Parkinson's disease has shown encouraging effects in a ...

Trial Designed to Demonstrate Target Engagement, Safety, and Pharmacokinetics CLEVELAND, April 7, 2026 /PRNewswire/ -- NeuroTherapia, Inc., a clinical-stage company focused on developing oral ...